Importance of serous intraepithelial ovarian tubal carcinomas in the occurrence of "high-grade" serous carcinomas and / or peritoneal serous carcinomas of unknown primary origin.

Authors

DOI:

https://doi.org/10.26641/2307-0404.2020.1.200405

Keywords:

"high-grade" serous ovarian carcinomas, cancers without known primary localization, p53, ImageJ

Abstract

Studies of the recent decades on serous pelvic adenocarcinomas in women have set the goal of distinguishing between two diagnostic units: "low-grade" and "high-grade" carcinomas. The predecessor of the "low-grade" variant (type I) is considered to be a borderline serous tumor / atypical proliferative serous tumor (8442/1), which according to the International Classification of Diseases for Oncology ICD-O 2013 of the female reproductive system refers to non-specific, borderline tumors and tumors with unpredictable clinical behavior. The predecessors of the “high-grade” variant (type II) are serous tubular intraepithelial carcinomas (in situ) or “high-grade” serous invasive tubal carcinomas, since they have the TP53 mutation identical to “high-grade” ovarian carcinoma, an aberrant p53 protein expression, high proliferative activity, and significant genomic instability. In addition, according to the carcinogenesis of "high-grade" serous ovarian carcinoma with metastases to the peritoneum, it can also be interpreted as "pelvic high-grade serous carcinoma". A retrospective analysis of the histological, morphometric and immunohistochemical characteristics of the biopsy material of 31 women aged from 28 to 76 years (mean 57.32±11.54; median 57), divided into 3 groups, was carried out. Group 1: 14 observations of the tubal epithelium (8 tubes without pathological changes (subgroup 1a) and 6 with signs of intraepithelial neoplasia (subgroup 1b); group 2: 12 cases of serous adenocarcinoma of the ovary of the “high-grade” variant; group 3: 6 metastatic peritoneal serous carcinoma without a known primary site. Results. Group immunophenotypes showed uniformity in the expression of markers CK7 (+, +/-), CK20 (-), WT-1 (+), CA125 (+, +/-), with an affinity to distal uterine tube fragments. The expression of p53 in all groups with signs of carcinomas (compared with the control subgroup 1a without atypia) was divided into two options - negative samples and samples with overexpression, where no statistically significant difference was found (p>0.05), which is possibly a single way of carcinogenesis. The morphometric study revealed a significant difference in the area of the nuclei between group 3 and the first three groups (1a, 1b, 2), which indicates the similarity of ovarian and tubal neoplasias and uterine tube epithelium. The number of intranuclear reactions with ER and PGR progressively decreased from group 1 to group 3, with an increase in cases with ER (+/-) / PGR (+/- or -) to 50% in group 3, which greatly complicated the diagnostic search for unknown carcinomas of primary localization. HER-2-new expression revealed a possible amplification (gradation 2 + / 3 +) only in group 2 at the level of 16.67% and in group 3 at the level of 33.33%.

Author Biographies

I. S. Shponka

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Pathological Anatomy and Forensic Medicine
V. Vernadsky str., 9, Dnipro, 49044, Ukraine

О. V. Poslavska

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Pathological Anatomy and Forensic Medicine
V. Vernadsky str., 9, Dnipro, 49044, Ukraine

O. A. Savchenko

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of Pathological Anatomy and Forensic Medicine
V. Vernadsky str., 9, Dnipro, 49044, Ukraine

References

Poslavskaya OV. [Determination of linear dimen­sions and square square surfaces areas of morphological objects on micrographs using ImageJ software]. Morphologia. 2016;10(3):377-81. Ukrainian. doi: https://doi.org/10.26641/1997-9665.2016.3.377-381

Poslavska OV, Shponka IS, Gritsenko PO, Alek­seenko OA. [Morphometric analysis of pancytokera­tin-negative neoplastic damages of the lymphatic nodes of the neck]. Medicni perspektivi. 2018;23(1):30-37. Ukrainian. doi: https://doi.org/10.26641/2307-0404.2018.1.124915

Hatano Y, Hatano K, Tamada M, et al. A Comprehensive Review of Ovarian Serous Carcinoma. Adv Anat Pathol. 2019;26:329-39. doi: https://doi.org/10.1097/PAP.0000000000000243

Chen M, Jin Y, Bi Y, et al. A survival analysis comparing women with ovarian low-grade serous carci­noma to those with high-grade histology. OncoTargets and Therapy. 2014;7:1891-9. doi: https://doi.org/10.2147/OTT.S67812

Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet. 2018;143(2):59-78. doi: https://doi.org/10.1002/ijgo.12614

Gadducci A, Guarneri V, Peccatori FA, et al. Cur­rent strategies for the targeted treatment of high-grade se­rous epithelial ovarian cancer and relevance of BRCA mu­tational status. Journal of Ovarian Research. 2019;12(9):1-9. doi: https://doi.org/10.1186/s13048-019-0484-6

Chen H, Klein R, Arnold S, et al. Cytologic stu­dies of the fallopian tube in patients undergoing salpingo-oophorectomy. Cancer Cell Int. 2016;16(78):1-8. doi: https://doi.org/10.1186/s12935-016-0354-x

Visvanathan K, Shaw P, May BJ, et al. Fallopian Tube Lesions in Women at High Risk for Ovarian Can­cer: A Multicenter Study. Cancer Prev Res. 2018;11(11):697-706. doi: https://doi.org/10.1158/1940-6207.CAPR-18-0009

Gershenson D. Low-grade serous carcinoma of the ovary or peritoneum. Annals of Oncology. 2016;27(1):i45-i49. doi: https://doi.org/10.1093/annonc/mdw085

Kim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. PNAS. 2012;109(10):3921-6. doi: https://doi.org/10.1073/pnas.1117135109

Lisio M-A, Fu L, Goyeneche A, et al. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int. J. Mol. Sci. 2019;20(952):1-33. doi: https://doi.org/10.3390/ijms20040952

Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallo­pian tube. Nature communications. 2017;8(1093):1-11. doi: https://doi.org/10.1038/s41467-017-00962-1

Hirst J, Crow J, Godwin A. Ovarian Cancer Genetics: Subtypes and Risk Factors. Ovarian Cancer Genetics: Subtypes and Risk Factors. 2018;3-38. doi: http://dx.doi.org/10.5772/intechopen.72705

Lohneis P, Darb-Esfahani S, Dietel M, et al. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors. Anticancer research. 2015;35:6329-34.

Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International Jour­nal of Gynecology and Obstetrics. 2014;124:1-5. doi: https://doi.org/10.1016/j.ijgo.2013.10.001

Haniyeh Bashi Zadeh Fakhar, Hakimeh Zali, Mostafa Rezaie-Tavirani, et al. Proteome profiling of low grade serous ovarian cancer. Journal of Ovarian Research. 2019;12(64):1-14.

Tone AA, Salvador S, Finlayson SJ, et al. The Ro­le of the Fallopian Tube in Ovarian Cancer. Clinical Ad­vances in Hematology & Oncology. 2012;10(5):296-306.

Wang Y, Hong S, Mu J, et al. Tubal Origin of (Ovarian) Low-Grade Serous Carcinoma: A Gene Expres­sion Profile Study. Journal of Oncology. 2019;1-9. doi: https://doi.org/10.1155/2019/8659754

Published

2020-04-09

How to Cite

1.
Shponka IS, Poslavska ОV, Savchenko OA. Importance of serous intraepithelial ovarian tubal carcinomas in the occurrence of "high-grade" serous carcinomas and / or peritoneal serous carcinomas of unknown primary origin. Med. perspekt. [Internet]. 2020Apr.9 [cited 2024Mar.29];25(1):79-87. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/200405

Issue

Section

CLINICAL MEDICINE